Last reviewed · How we verify

Salmeterol(SN408D) — Competitive Intelligence Brief

Salmeterol(SN408D) (Salmeterol(SN408D)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist (LABA). Area: Respiratory.

marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol(SN408D) (Salmeterol(SN408D)) — GlaxoSmithKline. Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Salmeterol(SN408D) TARGET Salmeterol(SN408D) GlaxoSmithKline marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2)
Formoterol Aldo Formoterol Aldo Fundacio Privada Mon Clinic Barcelona marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
Indacaterol Fumarate Indacaterol Fumarate University of Milan marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
vilanterol (VI) vilanterol (VI) GlaxoSmithKline marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2)
Formoterol fumerate Formoterol fumerate Novartis marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
formoterol Turbuhaler 9µg formoterol Turbuhaler 9µg AstraZeneca marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
Servent Diskus Servent Diskus Teva Branded Pharmaceutical Products R&D, Inc. marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist (LABA) class)

  1. GlaxoSmithKline · 8 drugs in this class
  2. AstraZeneca · 5 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Sumitomo Pharma America, Inc. · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 3 drugs in this class
  6. Organon and Co · 2 drugs in this class
  7. Fundacio Privada Mon Clinic Barcelona · 2 drugs in this class
  8. Henan University of Traditional Chinese Medicine · 1 drug in this class
  9. Genentech, Inc. · 1 drug in this class
  10. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol(SN408D) — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-sn408d. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: